|1.||Fucile, Serena: 1 article (07/2008)|
|2.||Radice, Sonia: 1 article (07/2008)|
|3.||Marabini, Laura: 1 article (07/2008)|
|4.||Chiesara, Enzo: 1 article (07/2008)|
|5.||Päpke, Olaf: 1 article (07/2006)|
|6.||Kunz, Susanne: 1 article (07/2006)|
|7.||Lehmler, Hans-Joachim: 1 article (07/2006)|
|8.||Robertson, Larry W: 1 article (07/2006)|
|9.||Schwarz, Michael: 1 article (07/2006)|
|10.||Schrenk, Dieter: 1 article (07/2006)|
05/01/2006 - "In this study, the potential effects of four selected polychlorinated biphenyl (PCB) congeners (PCB101, PCB110, PCB126 and PCB149) as well as several of their environmentally-relevant methylsulfonyl-(MeSO(2)-) PCB metabolites (3'-MeSO(2)-CB101, 4'-MeSO(2)-CB101, 4'-MeSO(2)-CB110, 3'-MeSO(2)-CB149 and 4'-MeSO(2)-CB149) on adrenocortical steroidogenesis were evaluated by in vitro bioassay based on the human adrenocortical carcinoma H295R cell line. "
|3.||Breast Neoplasms (Breast Cancer)
|4.||Body Weight (Weight, Body)
07/01/2006 - "With each congener, no significant increase in the number of ATPase-deficient or GSTP-positive preneoplastic foci was obtained, while a significant increase in the relative hepatic volume of ATPase-deficient foci was found in the livers of DEN pre-treated animals having received 50 micromol/kg body weight of PCB 101 per week over 16 weeks. "
07/01/2006 - "After 8 or 16 weeks of PCB treatment (50 and 150 micromol/kg body weight per week), each congener was recovered in the liver according to the dose levels applied, with PCB 28, at the same dose level, showing nine- to 16-fold higher hepatic levels than PCB 101 (approximately, 44 micromol/kg versus 5 micromol/kg liver at low dose, 145 micromol/kg versus 9 micromol/kg liver at high dose). "
|2.||Adenosine Triphosphatases (ATPase)